Skip to main content

Table 4 Recurrence-free, distant metastasis-free, and melanoma-specific survival rates in the population of patients receiving a sentinel lymph node biopsy

From: Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients

  RFS (# events, 95% CI) DMFS (# events, 95% CI) MSS (# events, 95% CI)
Class 1 (n = 159) 79% (37, 72–85%) 87% (24, 82–93%) 97% (7, 94–100%)
Class 2 (n = 178) 51% (89, 44–59%) 59% (74, 51–67%) 78% (35, 71–85%)
SLN- (n = 180) 79% (43, 73–85%) 85% (32, 80–91%) 95% (9, 92–99%)
SLN+ (n = 157) 47% (82, 39–56%) 55% (66, 47–65%) 75% (33, 68–84%)
Class 1/SLN- (n = 103) 87% (15, 81–94%) 93% (9, 88–98%) 98% (2, 95–100%)
Class 1/SLN+ (n = 56) 61% (22, 49–76%) 74% (15, 63–88%) 93% (5, 86–100%)
Class 2/SLN- (n = 77) 67% (28, 57–79%) 75% (23, 66–85%) 92% (7, 85–98%)
Class 2/SLN+ (n = 101) 37% (60, 28–49%) 44% (51, 34–56%) 63% (28, 52–76%)
  1. CI confidence interval, DMFS distant metastasis-free survival, GEP gene expression profile, RFS recurrence-free survival, SLN sentinel lymph node, MSS melanoma-specific survival